-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 5th, AstraZeneca announced that its blockbuster PD-L1 inhibitor Imfinzi (durvalumab) has shown significant results in a phase 3 clinical trial for the treatment of stage III non-small cell lung cancer (NSCLC) Long-term efficacy.
Lung cancer is the leading cause of cancer deaths worldwide, and 80-85% of patients are NSCLC.
Imfinzi is a humanized anti-PD-L1 monoclonal antibody.
In a phase 3 clinical trial called PACIFIC, patients with stage III unresectable NSCLC who did not progress after chemotherapy and radiotherapy (CRT) were treated with Imfinzi or placebo.
Dr.
Reference materials:
Reference materials:[1] Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years.
[1] Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number